COMMUNIQUÉS West-GlobeNewswire

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in [...]
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
14/08/2026
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed [...]
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026 Successfully completed [...]
ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system
14/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the company’s tree pollen tablet (ITULAZAX ® ) and house dust mite tablet ( [...]
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
14/08/2026
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced [...]
Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme
14/08/2026
Cette soumission repose sur les résultats positifs d’efficacité et de sécurité de l’étude de Phase 3 VALOR NEW YORK & LYON, France, le 14 août 2026, Pfizer Inc. (NYSE: PFE) et Valneva SE (Nasdaq: VALN; Euronext [...]
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
14/08/2026
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, [...]
More Cancer Patients Are Opting to Preserve Their Tumors
14/08/2026
New Tumor-Preservation Service Opens in Arizona, Giving Patients the Opportunity to Preserve Unadulterated Tumor Tissue for Potential Personalized Cancer Immunotherapy SCOTTSDALE, Ariz., Aug. 13, 2026 (GLOBE NEWSWIRE [...]
Nutraville Announces MemoryFuel Launch as Interest Grows Around Creatine Monohydrate, Brain Energy, and Daily Mental Performance
14/08/2026
Tallmadge, OH, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutraville has announced the launch of MemoryFuel, a caffeine-free brain-health powder formulated for adults interested in supporting memory, focus support, mental [...]
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
13/08/2026
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic [...]
BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026
13/08/2026
MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on [...]
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
13/08/2026
Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regeneration Continued favorable safety and tolerability profile, [...]
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
13/08/2026
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined [...]
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial [...]
Maze Therapeutics Announces Appointments to Its Board of Directors
13/08/2026
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 ( [...]
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
13/08/2026
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the [...]
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing [...]
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
13/08/2026
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates [...]
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
13/08/2026
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]

Pages